Dr. Anthony Guiseppi-Elie, University distinguished professor, founding dean of the Anderson University College of Engineering and vice president for industry relations has been named to the 2020 Class of Fellows by the Biomedical Engineering Society.
Dr. Guiseppi-Elie is one of 27 new members of the Society who “have demonstrated exceptional achievements and have made significant contributions within the biomedical engineering field.” He will join his class at the organization’s virtual meeting in October.
Dr. Guiseppi-Elie joined Anderson University in August following his service as the Texas A&M Engineering Experiment Station (TEES) Professor of Engineering in the College of Engineering at Texas A&M University.
At Texas A&M, Dr. Guiseppi-Elie was most recently head of the Department of Biomedical Engineering and associate dean of engineering innovation. He holds degrees from the Massachusetts Institute of Technology (MIT), University of Manchester Institute of Science and Technology and the University of the West Indies.
“I am delighted to join my accomplished colleagues in being recognized for our contributions to advancing the discipline and serving the field of biomedical engineering,” Dr. Guiseppi-Elie said.
His previous honors include being named a Fellow of the American Institute of Medical and Biological Engineering (AIMBE), where he served AIMBE as VP of the Industry Council and as Chair-elect and Chair of the College of Fellows. He is also a Fellow of IEEE and a Fellow of the Royal Society of Chemistry. As a leader in medical bioanalytics, Dr. Guiseppi-Elie was elected to participate in the National Academy of Engineering’s review of the Department of Commerce’s National Institute of Standards and Technology (NIST). His teaching and research interests include bionanotechnology, BioMEMS, interfacing of biology and engineering from the molecular to the tissue scale, and applications of semiconductor fabrication techniques to biomedical engineering and academic entrepreneurship, all applied to solving health problems such as neurostimulation, neuroregeneration, chronic wound healing, and hemorrhaging trauma management. He has been involved in three separate startups that have licensed his technologies, most recently ABTECH Scientific, Inc.